Article
03 Dec 2025
Ten Minefields: A Guide To Avoiding Pitfalls In Applying For Human Genetic Resources Projects In China
CONTRIBUTING SINCE AUGUST 2014
Han Kun Law Offices
POPULAR TOPICS
Food, Drugs, Healthcare, Life Sciences
Corporate/Commercial Law
Privacy
Government, Public Sector
Insurance
Han Kun Law Offices are most popular:
- within Technology, International Law and Corporate/Commercial Law topic(s)
- in China and Asia
COMPANY CONTENT
Article
03 Dec 2025
China Released Draft Medical Device Law For Comments
Article
15 Oct 2025
汉坤 • 观点 | 《药品管理法实施条例》（修订草案）重点快评
Article
15 Oct 2025
汉坤 • 观点 | 中国药品年度报告制度简析
Article
15 Oct 2025
汉坤 • 观点 | 简评新版《医疗器械临床试验质量管理规范（GCP）》
Article
14 Oct 2025
Compliance Highlights And Strategies In High-Risk Clinical Research Landscape
Article
14 Oct 2025
Han Kun • Opinion | Hot Spot Tracking: Daily Regulatory Risk Warnings For Drug Clinical Trial Institutions
Article
14 Oct 2025
Han Kun • Opinion | Interpretation Of China's Annual Drug Review Report (2015-2021) - Review Of The Achievements Of Our Country's Drug Review And Approval System Reform (Part 1)
Article
14 Oct 2025
Han Kun • Opinion | Settle The Dust Or Let The Bullets Fly: Biden Administration Signs Executive Order On Promoting Biotechnology And Biomanufacturing Innovation
Article
13 Oct 2025
Han Kun • Opinion | Interpretation Of The "Detailed Rules For The Supervision Of Internet Diagnosis And Treatment (Trial)"
Article
13 Oct 2025
Han Kun • Opinion | Finally Waiting For You - Interpreting The New Policy Of Cross-border Contract Production Of Drugs And Medical Devices In The Guangdong-Hong Kong-Macao Greater Bay Area
Article
13 Oct 2025
Han Kun • Opinion | Research On Urban Customized Commercial Medical Insurance
Article
09 Oct 2025
Han Kun • Opinion | Interpretation Of China's Annual Drug Review Report (2015-2021) - Review Of The Reform Of Our Country's Drug Review And Approval System (Part II)
Article
09 Oct 2025
Han Kun • Opinion | Interpretation Of China's Annual Drug Review Report (2015-2021) - Review Of The Reform Achievements Of Our Country's Drug Review And Approval System (Part II)
Article
09 Oct 2025
汉坤 • 观点 | 医药BD项目如何友好"分手"？
Article
09 Oct 2025
How Digital Therapeutics (DTx) Products Are Regulated In China?
Article
09 Oct 2025
生命科学行业License-in/out合同争议要点分析（三）：不竞争条款
Article
09 Oct 2025
2024 Data Analytics: China Life Sciences NewCo & Licensing Terms
Article
09 Oct 2025
Strengthening Oversight of Imported Drugs: Key Takeaways into New Regulations on Domestic Responsible Entities
Article
07 Oct 2025
Han Kun • Opinion | The New Ethical Review Regulations Focus On Quick Comments
AWARDS
